Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

A pediatric oncologist looks for progress in Alzheimer’s disease

Ron Louie, MD
Conditions
May 8, 2018
Share
Tweet
Share

A baby acutely ill with leukemia seems like the polar opposite of a woman with Alzheimer’s disease (AD), with her slow, insidious deterioration. Yet each disease can be progressive and fatal. I’ve cared for both, in different ways.  Can a childhood cancer doctor like me have insights about that other end of medicine, older adults with dementia?

As a husband and caregiver, confronting my wife’s Alzheimer’s disease, I am appalled by the lack of effective therapy for her. As a clinical investigator myself, I’m appalled by what I see as a lack of direction in clinical dementia research, a lack of structure, and a lack of ambitious leadership.

Every Minute Counts, the PBS TV documentary that aired recently, showed the heart-rending personal devastation of Alzheimer’s Disease (AD) and dementia, and the enormous cost of care for those affected.  It ended with a plea for more funding and research. But after decades of research and billions already spent, why aren’t we further?

Alzheimer’s is now the 6th leading cause of death in the U.S.; it was only 13th two decades ago. Many AD experts acknowledge the lack of progress. Recently, two researchers even wrote that seeking an AD cure is a notion “many believe unrealistic,” and that advocating for curative therapy “verges on the promotion of false hope.”

Since my wife was diagnosed, just one new drug, really a combination of two older drugs, has been approved for Alzheimer’s.  As a cancer doctor, I’ve watched more than 70 cancer treatments get approved during those same five years.

Even the Alzheimer’s Association plainly states “there is no cure for Alzheimer’s.”  Not so plainly stated is that we don’t know what causes it, how it happens, or how to prevent it.

Of course, we don’t really know what causes childhood leukemia either, how it happens, or how to prevent it, even with our current sophisticated molecular descriptions and theories.  But the survival rate for the most common childhood leukemia has gone from less than 10% in the 1960’s to over 90% now, with incremental progress every five years.  Most kids are cured with combination chemotherapy that was developed decades ago, before molecular testing.

Most AD funding goes for molecular or non-therapeutic research, at the expense of clinical work. Sickle cell anemia was called the first “molecular disease” over sixty years ago; we still don’t have a cure, even though just this year we might have a gene therapy for it. In AD, the molecular genetics seems more complicated. AD patients have waited years for ANY therapy, much less one from “precision medicine.” Is this the right strategy?

It’s not all bad news. Recently, three commercial drug trials announced results, and they showed glimmers of hope.  Two were reported as failures by the media, but company press releases (TauRx,Lilly) reported modest positive effects. The third drug, from Biogen, seemed better at slowing the decline in some patients, but evidently did not stop the disease.

AIDS therapy, like cancer, is an area of medicine that seemed hopeless at first.  The leadership of Dr. William Paul, an “AIDS Czar,” is credited with accelerating clinical progress in that condition.  Still incurable, nevertheless AIDS patients’ lives are now extended from months to years.

Nothing has really changed for Alzheimer patients over the past five years. Brilliant scientists are working, but in the usual atmosphere of creative academic chaos. There are a few AD clinical trial groups, much like cancer trials groups, but the comparison of their activity is stark. In the state of Washington, there are over 600 cancer studies recruiting patients; in AD there are about a dozen such studies.

Much foundational AD work still needs to be done at the bedside, in overall strategy, trial coordination, informed consents, vigorous subject recruitment, and consensus development, so appointing an accountable, identifiable, directive clinical research leader seems like an important way to accelerate progress (although “czar” or “emperor” may not be the right titles these days).

Ron Louie is a pediatric oncologist.  This article originally appeared in the Baltimore Sun.

ADVERTISEMENT

Image credit: Shutterstock.com

Prev

Undoing what we’ve done: Why deprescribing is so difficult

May 8, 2018 Kevin 3
…
Next

Addressing the health care system flaws that feed the opioid crisis

May 8, 2018 Kevin 21
…

Tagged as: Neurology

Post navigation

< Previous Post
Undoing what we’ve done: Why deprescribing is so difficult
Next Post >
Addressing the health care system flaws that feed the opioid crisis

ADVERTISEMENT

More by Ron Louie, MD

  • Will Alzheimer’s disease researchers miss seeing the forest from the trees?

    Ron Louie, MD
  • Do substituted decisions break the Golden Rule?

    Ron Louie, MD
  • Interpreting 2 recent studies involving Alzheimer disease

    Ron Louie, MD

Related Posts

  • Should only infectious disease specialists be allowed to prescribe antibiotics?

    Craig Bowron, MD
  • The culture of perfection in medicine is a disease

    Andy Cruz, MD
  • Chronic disease is making medical education worse

    Jason J. Han, MD
  • Observing the effects of COVID-19 on the pediatric population

    Amy Cox and Rachel Kalthoff
  • 10 tips for delivering difficult pediatric diagnoses

    Laura Spiegel
  • Are pediatric hospitals ready to embrace value-based payment models?

    Johanna Vidal Phelan, MD, MBA

More in Conditions

  • Coconut oil’s role in Alzheimer’s and depression

    Marc Arginteanu, MD
  • Ancient health secrets for modern life

    Larry Kaskel, MD
  • How the internet broke the doctor-parent trust

    Wendy L. Hunter, MD
  • Mpox isn’t over: A silent epidemic is growing

    Melvin Sanicas, MD
  • How your family system secretly shapes your health

    Su Yeong Kim, PhD
  • The human case for preserving the nipple after mastectomy

    Thomas Amburn, MD
  • Most Popular

  • Past Week

    • Why your clinic waiting room may affect patient outcomes

      Ziya Altug, PT, DPT and Shirish Sachdeva, PT, DPT | Conditions
    • The human case for preserving the nipple after mastectomy

      Thomas Amburn, MD | Conditions
    • Nuclear verdicts and rising costs: How inflation is reshaping medical malpractice claims

      Robert E. White, Jr. & The Doctors Company | Policy
    • How new loan caps could destroy diversity in medical education

      Caleb Andrus-Gazyeva | Policy
    • IMGs are the future of U.S. primary care

      Adam Brandon Bondoc, MD | Physician
    • The ethical crossroads of medicine and legislation

      M. Bennet Broner, PhD | Conditions
  • Past 6 Months

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • Why primary care needs better dermatology training

      Alex Siauw | Conditions
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
  • Recent Posts

    • How tragedy shaped a medical career

      Ronald L. Lindsay, MD | Physician
    • A doctor’s guide to preparing for your death

      Joseph Pepe, MD | Physician
    • Coconut oil’s role in Alzheimer’s and depression

      Marc Arginteanu, MD | Conditions
    • How policy and stigma block addiction treatment

      Mariana Ndrio, MD | Physician
    • Unused IV catheters cost U.S. hospitals billions

      Piyush Pillarisetti | Policy
    • Why U.S. universities should adopt a standard pre-med major [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Why your clinic waiting room may affect patient outcomes

      Ziya Altug, PT, DPT and Shirish Sachdeva, PT, DPT | Conditions
    • The human case for preserving the nipple after mastectomy

      Thomas Amburn, MD | Conditions
    • Nuclear verdicts and rising costs: How inflation is reshaping medical malpractice claims

      Robert E. White, Jr. & The Doctors Company | Policy
    • How new loan caps could destroy diversity in medical education

      Caleb Andrus-Gazyeva | Policy
    • IMGs are the future of U.S. primary care

      Adam Brandon Bondoc, MD | Physician
    • The ethical crossroads of medicine and legislation

      M. Bennet Broner, PhD | Conditions
  • Past 6 Months

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • Why primary care needs better dermatology training

      Alex Siauw | Conditions
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
  • Recent Posts

    • How tragedy shaped a medical career

      Ronald L. Lindsay, MD | Physician
    • A doctor’s guide to preparing for your death

      Joseph Pepe, MD | Physician
    • Coconut oil’s role in Alzheimer’s and depression

      Marc Arginteanu, MD | Conditions
    • How policy and stigma block addiction treatment

      Mariana Ndrio, MD | Physician
    • Unused IV catheters cost U.S. hospitals billions

      Piyush Pillarisetti | Policy
    • Why U.S. universities should adopt a standard pre-med major [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

A pediatric oncologist looks for progress in Alzheimer’s disease
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...